Annexon, Inc. (ANNX)Healthcare | Biotechnology | Brisbane, United States | NasdaqGS
6.54 USD
+0.21
(3.318%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.58 +0.04 (0.612%) ⇧ (April 17, 2026, 7:26 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:34 p.m. EDT
Despite negative earnings and high valuation multiples (P/B 4.6x), insider buying and aggressive call flow point to a near-term catalyst, likely a clinical trial readout or near-term upside play targeting the $7-$10 range, making this a momentum buy rather than a value investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.157529 |
| AutoARIMA | 0.160839 |
| AutoETS | 0.160841 |
| MSTL | 0.242935 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.416 |
| Excess Kurtosis | -0.85 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.38 |
| Market Cap | 1,049,502,144 |
| Forward P/E | -6.84 |
| Beta | 1.15 |
| Website | https://www.annexonbio.com |
As of April 18, 2026, 11:34 p.m. EDT: Near-term expirations (Apr 17) show strong call activity at higher strikes, particularly aggressive positioning at the 10.0 strike with 21 Open Interest despite being deeply out-of-the-money relative to the 6.54 price. This contrasts with put activity which is concentrated at lower strikes (3.0-4.0) in mid-term expirations, suggesting a 'long gamma' position for a rise in the 2-month window, but potential hedging coming in 6 months. The 12-month data shows significant out-of-the-money put Open Interest at deep strikes (1.5, 12.0), indicating some flight-to-safety or downside targeting further out, but the immediate flow is overwhelmingly bullish on calls.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.892857 |
| Address1 | 1,400 Sierra Point Parkway |
| Address2 | Building C Suite 200 |
| All Time High | 38.01 |
| All Time Low | 1.285 |
| Ask | 8.15 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,489,320 |
| Average Daily Volume3 Month | 2,634,188 |
| Average Volume | 2,634,188 |
| Average Volume10Days | 2,489,320 |
| Beta | 1.148 |
| Bid | 6.5 |
| Bid Size | 9 |
| Board Risk | 7 |
| Book Value | 1.417 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.54 |
| Current Ratio | 5.681 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.615 |
| Day Low | 6.35 |
| Debt To Equity | 12.38 |
| Display Name | Annexon |
| Earnings Timestamp | 1,774,900,800 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -214,240,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.908 |
| Enterprise Value | 837,358,144 |
| Eps Current Year | -1.16299 |
| Eps Forward | -0.95644 |
| Eps Trailing Twelve Months | -1.34 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 636 9773 |
| Fifty Day Average | 5.5045 |
| Fifty Day Average Change | 1.0355 |
| Fifty Day Average Change Percent | 0.18811883 |
| Fifty Two Week Change Percent | 289.2857 |
| Fifty Two Week High | 7.18 |
| Fifty Two Week High Change | -0.63999987 |
| Fifty Two Week High Change Percent | -0.089136474 |
| Fifty Two Week Low | 1.4 |
| Fifty Two Week Low Change | 5.14 |
| Fifty Two Week Low Change Percent | 3.6714284 |
| Fifty Two Week Range | 1.4 - 7.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,595,597,400,000 |
| Float Shares | 130,715,973 |
| Forward Eps | -0.95644 |
| Forward P E | -6.8378572 |
| Free Cashflow | -104,476,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 96 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00402 |
| Held Percent Institutions | 0.92437 |
| Implied Shares Outstanding | 160,474,333 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. |
| Long Name | Annexon, Inc. |
| Market | us_market |
| Market Cap | 1,049,502,144 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_279883519 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -208,547,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,049,502,137 |
| Number Of Analyst Opinions | 7 |
| Open | 6.41 |
| Operating Cashflow | -186,356,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 822 5500 |
| Post Market Change | 0.03999996 |
| Post Market Change Percent | 0.6116202 |
| Post Market Price | 6.58 |
| Post Market Time | 1,776,468,409 |
| Previous Close | 6.33 |
| Price Eps Current Year | -5.6234365 |
| Price Hint | 2 |
| Price To Book | 4.6153846 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.591 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | 0.21 |
| Regular Market Change Percent | 3.31754 |
| Regular Market Day High | 6.615 |
| Regular Market Day Low | 6.35 |
| Regular Market Day Range | 6.35 - 6.615 |
| Regular Market Open | 6.41 |
| Regular Market Previous Close | 6.33 |
| Regular Market Price | 6.54 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 3,001,015 |
| Return On Assets | -0.43098998 |
| Return On Equity | -0.81897 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 160,474,333 |
| Shares Percent Shares Out | 0.1161 |
| Shares Short | 18,637,378 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 15,901,379 |
| Short Name | Annexon, Inc. |
| Short Percent Of Float | 0.1345 |
| Short Ratio | 6.15 |
| Source Interval | 15 |
| State | CA |
| Symbol | ANNX |
| Target High Price | 27.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 13.71429 |
| Target Median Price | 11.0 |
| Total Cash | 238,344,992 |
| Total Cash Per Share | 1.485 |
| Total Debt | 26,201,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.0799 |
| Two Hundred Day Average Change | 2.4601002 |
| Two Hundred Day Average Change Percent | 0.60298055 |
| Type Disp | Equity |
| Volume | 3,001,015 |
| Website | https://www.annexonbio.com |
| Zip | 94,005 |